natgillin/translations-raw huggingface dataset:
† Patients who took designated treatment as randomised in combination with the correct background 
† Bolniki, ki so jemali v skladu z randomizacijo dodeljena zdravila v kombinaciji z ustreznim osnovnim zdravljenjem in so imeli podatke, ki jih je bilo mogoče ovrednotiti.
AVAGLIM dose adjustment within the recommended posology or changes in diabetic treatment should be considered. 
V poštev pride prilagoditev odmerka AVAGLIMA v skladu s priporočenim odmerjanjem ali sprememba antidiabetične terapije.
Rosiglitazone plasma concentrations peak at around 1 h after dosing. 
Rosiglitazon doseže največjo koncentracijo v plazmi okrog 1 uro po uporabi.
Patients receiving AVAGLIM may be at risk of dose-related hypoglycaemia (see section 4.8). 
Bolnike, ki dobivajo AVAGLIM, lahko ogroža z odmerkom povezana hipoglikemija (glejte poglavje 4.8).
For patients inadequately controlled on glimepiride monotherapy (typically 4 mg). 
Za bolnike, ki niso ustrezno urejeni z monoterapijo z glimepiridom (praviloma 4 mg).
Patients with mild or moderate renal impairment (creatinine clearance 30 to 80 ml/min) may be at an increased risk of hypoglycaemia (see sections 4.2, 4.3 and 4.4). 
Bolnike z blago ali zmerno okvaro ledvic (očistek kreatinina od 30 do 80 ml/min) lahko bolj ogroža hipoglikemija (glejte poglavja 4.2, 4.3 in 4.4).
AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance. 
AVAGLIM je indiciran za zdravljenje bolnikov z diabetesom mellitusom tipa 2, ki kljub optimalnemu odmerjanju monoterapije s sulfonilsečnino ne dosežejo zadostne urejenosti glikemije in za katere metformin ni primeren, ker je kontraindiciran ali ga ne prenesejo.
Haemolytic anaemia: If you have an inherited condition where your red blood cells don't produce enough of the enzyme G6PD, Avaglim may cause your red blood cells to be destroyed too quickly (haemolytic anaemia). 
Hemolitična anemija: Če veste, da vaše rdeče krvne celice ne proizvajajo dovolj encima glukoze-6-fosfat-dehidrohenaze (G6PD), če boste jemali Avaglim, bi lahko tvegali, da boste zboleli za resnim tipom anemije, ker se vaše rdeče krvničke prehitro razkrojijo (hemolitična anemija).
The clinical significance of the glucose-lowering effect of M1 is unclear. 
Klinični pomen vpliva M1 na zniževanje
Î Tell your doctor or pharmacist if you are taking anticoagulants. 
Î Povejte svojemu zdravniku ali farmacevtu, če jemljete zdravila proti strjevanju krvi.
Moreover in patients with congestive heart failure NYHA class I-II, a placebocontrolled one-year trial demonstrated worsening or possible worsening of heart failure in 6.4% of patients treated with rosiglitazone, compared with 3.5% on placebo. 
V enoletnem s placebom kontroliranem preskušanju pri bolnikih s kongestivnim srčnim popuščanjem razredov I in II po NYHA so ugotovili poslabšanje ali možno poslabšanje srčnega popuščanja pri 6,4 % prejemnikov rosiglitazona in pri 3,5 % prejemnikov placeba.
AVAGLIM 4 mg/4 mg film-coated tablets AVAGLIM 8 mg/4 mg film-coated tablets rosiglitazone/glimepiride 
AVAGLIM 4 mg/4 mg filmsko obložene tablete AVAGLIM 8 mg/4 mg filmsko obložene tablete rosiglitazon/glimepirid
Improved glycaemic control was also associated with significant decreases in free fatty acids. 
Boljšo urejenost glikemije je spremljalo tudi pomembno znižanje prostih maščobnih kislin.
Glimepiride binds with a high exchange rate to a beta cell membrane protein which is associated with the ATP-sensitive potassium channel but which differs from the usual sulphonylurea binding site. 
Glimepirid se z veliko hitrostjo izmenjave veže na membransko beljakovino celic beta, povezano s kalijevimi kanalčki, občutljivimi za ATP, vendar se mesto njegove vezave razlikuje od običajnega
Consistent with the mechanism of action, rosiglitazone reduced insulin resistance and improved pancreatic ß-cell function. 
Rosiglitazon je skladno s svojim mehanizmom delovanja zmanjšal odpornost za insulin in izboljšal delovanje pankreatičnih celic β.
Since glimepiride belongs to the chemical class of sulphonylurea drugs, caution should be used in patients with G6PD-deficiency and a non-sulphonylurea alternative should be considered. 
Ker glimepepirid sodi v kemijsko skupino zdravil, imenovanih sulfonilsečnine, je potrebna previdnost pri bolnikih s pomanjkanjem glukoze-6-fosfat-dehidrogenaze in je potrebno pretehtati o možnosti zdravljenja z zdravili, ki ne sodijo
The clinical trial program in support of this fixed dose combination only compared rosiglitazone and glimepiride to glimepiride monotherapy and not to monotherapy with other sulphonylureas. 
Program kliničnega preskušanja za podporo tej kombinaciji fiksnih odmerkov je primerjal le rosiglitazon in glimepirid z monoterapijo z glimepiridom, ne pa z monoterapijo z drugimi
High doses given to mother rats cause hypoglycaemia in suckling young rats (see section 4.6). 
Veliki odmerki, uporabljeni pri samicah-materah povzročijo hipoglikemijo pri dojenih mladičih (glejte poglavje 4.6).
Sulphonylureas regulate insulin secretion by closing the ATP-dependent potassium channels in the beta cell membrane. 
Sulfonilsečnine uravnavajo izločanje insulina z zaprtjem za ATP odvisnih kalijevih kanalčkov v membrani celic beta.
Rosiglitazone and glimepiride are both highly protein bound and would not be expected to be cleared by haemodialysis. 
Tako rosiglitazon kot glimepirid sta v veliki meri vezana na beljakovine in ni pričakovati, da bi ju hemodializa odstranila.
Allergic reactions: These are very rare in people taking Avaglim. 
Alergijske reakcije: Pri bolnikih, ki se zdravijo z zdravilom Avaglim so alergijske reakcije zelo redke.
Stop taking Avaglim. 
Ne jemljite zdravila Avaglim.
Î Check with your doctor, as Avaglim may not be suitable for you. 
Î Posvetujte se s svojim zdravnikom, saj zdravilo Avaglim v tem primeru za vas morda ni
Therefore weight should be closely monitored, given that it may be attributable to fluid retention, which may be associated with cardiac failure. 
Telesno maso bolnikov je torej treba skrbno nadzirati in pri tem upoštevati možno povezavo z zastajanjem tekočin, ki je lahko povezano s srčnim
These may be signs of liver problems: 
Znaki težav z jetri so
In diabetic patients, good metabolic control over 24 hours can be 
Pri diabetikih je mogoče dobro 24-urno presnovno urejenost doseči z enim samim odmerkom na
Clinically significant interactions with CYP2C9 substrates or inhibitors are not anticipated. 
Klinično pomembnih medsebojnih delovanj s substrati CYP2C9 ni pričakovati.
Take Avaglim for as long as your doctor recommends. 
Zdravilo Avaglim morate jemati tako dolgo kot vam to predpiše zdravnik.
Glimepiride acts mainly by stimulating the release of insulin from the beta cells of the pancreas. 
Glimepirid deluje predvsem s spodbujanjem izločanja insulina iz celic beta v pankreasu.
• stomach pain, bloating, feeling sick (nausea), vomiting or diarrhoea 
• bolečine v trebuhu, tiščanje v prebavilih, slabost (siljenje na bruhanje), bruhanje in driska
Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of rosiglitazone. 
Enkraten peroralni odmerek glimepirida pri 14 zdravih odraslih preiskovancih ni klinično pomembno vplival na farmakokinetiko rosiglitazona v stanju dinamičnega ravnovesja.
Immune system disorders (see Skin and subcutaneous tissue disorders) 
Bolezni imunskega sistema (glejte Bolezni kože in podkožja)
3 In a retrospective analysis of data from 42 pooled short-term clinical studies, the overall incidence of events typically associated with cardiac ischaemia was higher for rosiglitazone containing regimens, 2.00% versus combined active and placebo comparators, 1.53% [hazard ratio (HR) 1.30 (95% confidence interval (CI) 1.004 - 1.69)]. 
3 Pri retrospektivni analizi podatkov iz 42 združenih kratkotrajnih kliničnih študij je bila celotna pojavnost dogodkov, tipično povezanih s srčno ishemijo, višja pri režimih zdravljenja z rosiglitazonom (2,00%) kot pri primerjalni kombinaciji učinkovine in placeba (1,53%) [razmerje ogroženosti 1,30 (95 % interval zaupanja (IZ) 1,004- 1,69)].
Results from an vivo interaction study reported in literature show that glimepiride AUC is increased approximately 2-fold by fluconazole, one of the most potent CYP2C9 inhibitors. 
Rezultati interakcijske študije in vivo, opisani v literaturi, kažejo, da flukonazol (eden najmočnejših zaviralcev CYP2C9) približno 2-krat poveča AUC glimepirida.
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1,000, < 1/100), rare (≥1/10,000, <1/1000) and very rare (<1/10,000 including isolated reports). 
Pogostnost je definirana kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000) in zelo redki (< 1/10.000, vključno s posameznimi primeri).
The effect of glimepiride is dosedependent and reproducible. 
Učinek glimepirida je odvisen od odmerka in je ponovljiv.
Approximately 40% of the total radioactivity was recovered in faeces and M1 and M2 (predominant) accounted for about 70% of that recovered in faeces. 
V blatu se je izločilo približno 40 % celotne radioaktivnosti; na račun M1 in M2 (pretežno) je šlo okrog 70 % radioaktivnosti, izločene v blatu.
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON Medicinal product subject to medical prescription. 
B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM • POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, PREDPISANI IMETNIKU
Glimepiride is an orally active hypoglycaemic substance belonging to the sulphonylurea group. 
Glimepirid je peroralno aktivno antidiabetično zdravilo, ki spada v skupino sulfonilsečnin.
AVAGLIM is contraindicated in patients with hepatic impairment (see section 4.3). 
AVAGLIM je kontraindiciran pri bolnikih z okvaro jeter (glejte poglavje 4.3).
Frequencies are defined as: rare ≥1/10,000, <1/1000 and very rare <1/10,000 including isolated reports. 
Pogostnost je definirana kot: redki (≥ 1/10.000, < 1/1.000) in zelo redki (< 1/10.000, vključno s posameznimi primeri).
Elimination The elimination half-life of glimepiride is approximately 5 to 8 h. When 14C-glimepiride was given orally, approximately 60% of the total radioactivity was recovered in the urine in seven days and M1 (predominant) and M2 accounted for 80 to 90% of that recovered in the urine. 
Po peroralni uporabi 14C-glimepirida se je približno 60 % celotne radioaktivnosti pojavilo v urinu v sedmih dneh; na račun M1 (pretežno) in M2 je šlo od 80 do 90 % radioaktivnosti, izločene v urinu.
The major metabolite (a para-hydroxy-sulphate) with high affinity to the soluble human PPARγ, exhibited relatively high potency in a glucose tolerance assay in obese mice. 
Glavni presnovek (parahidroksisulfat), ki ima veliko afiniteto za topni humani PPARγ, je v preizkusu tolerance za glukozo pri debelih miših pokazal razmeroma veliko moč.
Rosiglitazone showed moderate inhibition of CYP2C8 (IC50 18 µM) and low inhibition of CYP2C9 (IC50 50 µM) in vitro (see section 4.5). 
Rosiglitazon je in vitro pokazal le zmerno zavrtje CYP2C8 (IK50 18 µM) in majhno zavrtje CYP2C9 (IK50 50 µM) (glejte poglavje 4.5).
Gender: In the pooled population pharmacokinetic analysis, there were no marked differences in the pharmacokinetics of rosiglitazone or glimepiride between males and females. 
Spol: V kumulativni populacijski farmakokinetični analizi se farmakokinetika rosiglitazona ali glimepirida med moškimi in ženskami ni izrazito razlikovala.
AVAGLIM combines two antidiabetic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: rosiglitazone maleate, a member of the thiazolidinedione class and glimepiride, a member of the sulphonylurea class. 
AVAGLIM je kombinacija dveh antidiabetikov, ki s komplementarnim mehanizmom delovanja izboljšata urejenost glikemije pri bolnikih z diabetesom tipa 2: rosiglitazonijevega maleata, ki spada med tiazolidindione, in glimepirida, ki spada med sulfonilsečnine.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates 
Interakcijska študija z varfarinom in vivo je pokazala, da rosiglitazon in vivo nima medsebojnega delovanja s substrati CYP2C9.
Red, biconvex, rounded triangular tablet with “gsk” debossed on one side and “8/4” on the other side 
Rdeče, bikonveksne, zaokrožene trikotne tablete z vtisnjeno oznako "gsk" na eni strani in "8/4" na drugi.
In clinical trials with rosiglitazone there was evidence of dose-related weight gain, which was greater when used in combination with insulin. 
V kliničnih preskušanjih z rosiglitazonom so ugotovili z odmerkom povezano povečanje telesne mase, ki je bilo pri uporabi v kombinaciji z insulinom večje.
Rosiglitazone and glimepiride work together so your body makes better use of the insulin it produces, and this helps reduce your blood 
Rosiglitazon in glimepirid delujeta skupaj tako, da omogočata boljšo izrabo v telesu nastalega insulina, kar pomaga zmanjšati vrednost krvnega sladkorja na normalno vrednost.
− severe renal impairment i.e. creatinine clearance less than 30 ml/min (including renal dialysis). 
- hudo okvaro ledvic, tj. očistkom kreatinina manj kot 30 ml/min (vključno z dializo), - diabetično ketoacidozo ali diabetično komo.
Where clinically appropriate, direct change from glimepiride monotherapy to AVAGLIM may be considered. 
Če je klinično primerno, pride v poštev neposreden prehod z monoterapije z glimepiridom na AVAGLIM.
Absolute bioavailability of rosiglitazone following both a 4 and an 8 mg oral dose is approximately 99%. 
Absolutna biološka uporabnost rosiglitazona je po 4-mg in po 8-mg peroralnem odmerku približno 99 %.
Hepatic impairment: Following rosiglitazone treatment in cirrhotic patients with moderate (ChildPugh B) hepatic impairment, unbound Cmax and AUC were 2- and 3-fold higher than in normal subjects. 
Okvara jeter: Po zdravljenju bolnikov s cirozo in zmerno (Child-Pugh B) okvaro jeter z rosiglitazonom sta bili Cmax oz. AUC 2- oz. 3-krat večji kot pri zdravih preiskovancih.
Nevertheless, the potential for hypoglycaemia should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills (e.g. driving). 
Pri ocenjevanju bolnikove zmožnosti za izvajanje opravil, ki zahtevajo presojo in motorične ali kognitivne sposobnosti (npr. upravljanje vozil), je kljub temu treba upoštevati možnost hipoglikemije.
Signs include: 
Takšna zdravila so npr.:
The major route of excretion is the urine with approximately two-thirds of the dose being eliminated by this route, whereas faecal elimination accounts for approximately 25% of dose. 
Tako se izločita približno dve tretjini odmerka, medtem ko gre na račun izločanja v blatu približno 25 % odmerka.
Tell your doctor or pharmacist if you are taking any other medicines, if you've taken any recently, or if you start taking new ones. 
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali boste začeli jemati katerokoli novo zdravilo, vključno z zdravili iz zelišč in drugimi zdravili, ki jih lahko dobite brez
The following statements reflect the information available on the individual active substances (rosiglitazone and glimepiride). 
Naslednje navedbe temeljijo na informacijah, ki so na voljo za posamezni zdravilni učinkovini (rosiglitazon in glimepirid).
The following statements refer to AVAGLIM or the two individual active substances (rosiglitazone 
Naslednje navedbe veljajo za AVAGLIM ali posamezni zdravilni učinkovini (rosiglitazon in
Glimepiride increases the activity of glycosyl-phosphatidylinositol-specific phospholipase C, which may be associated with drug-induced lipogenesis and glycogenesis in isolated fat and muscle cells. 
Glimepirid poveča aktivnost za glikozil-fosfatidilinozitol specifične fosfolipaze C. To je morda povezano z indukcijo lipogeneze in glikogeneze, ki jo zdravilo povzroči v izoliranih maščobnih in
Rosiglitazone was associated with increases in weight. 
Rosiglitazon je bil povezan s povečanjem telesne mase.
Liver problems: Before you start taking Avaglim you will have a blood sample taken to check your liver function. 
Težave z jetri: Pred začetkom zdravljenja z zdravilom Avaglim bo zdravnik s krvno preiskavo preveril delovanje jeter.
As a consequence of different but complementary mechanisms of action, dual oral therapy of rosiglitazone with a sulphonylurea or metformin resulted in additive effects on glycaemic 
Zaradi različnih, vendar komplementarnih mehanizmov delovanja je imelo dvotirno zdravljenje z rosiglitazonom ter sulfonilsečnino ali metforminom pri bolnikih z diabetesom tipa 2 aditivne učinke na urejenost glikemije.
Mild or moderate renal impairment (creatinine clearance 30 to 80 ml/min): - Patients changing to AVAGLIM from sulphonylurea therapies other than glimepiride may be at an increased risk of hypoglycaemia (see section 4.4). 
Blaga ali zmerna okvara ledvic (očistek kreatinina od 30 do 80 ml/min): - Bolnike, ki preidejo na AVAGLIM z drugih sulfonilsečnin kot z glimepirida, lahko bolj ogroža hipoglikemija (glejte poglavje 4.4).
If glimepiride is taken simultaneously with certain other medicines, both undesired increases and decreases in the hypoglycaemic action of glimepiride can occur. 
Med sočasno uporabo glimepirida z nekaterimi drugimi zdravili se lahko pojavi tako neželeno povečanje kot zmanjšanje učinka glimepirida na znižanje krvnega sladkorja.
It is best to take Avaglim with food, or just before food, usually with your first main meal of the day. 
Najbolje je, da zdravilo Avaglim jemljete skupaj s hrano ali neposredno pred hrano, navadno s
Premenopausal women have received rosiglitazone during clinical studies. 
V kliničnih študijah so rosiglitazon dobivale ženske pred menopavzo.
• lower blood sugar than normal (hypoglycaemia) 
• prekomerno znižanje vrednosti krvnega sladkorja (hipoglikemija)
H2 antagonists, betablockers, clonidine and reserpine may lead to either potentiation or weakening of 
Zaviralci H2, zaviralci beta, klonidin in reserpin lahko učinek na znižanje glukoze v krvi povečajo ali
In patients with low haemoglobin levels before initiating therapy, there is an increased risk of anaemia during 
Pri bolnikih, ki imajo pred začetkom zdravljenja nizek hemoglobin, obstaja med zdravljenjem z
Elderly: In the pooled population pharmacokinetic analysis, age was not found to influence the pharmacokinetics of rosiglitazone or glimepiride to any significant extent. 
Starejši: Kumulativna populacijska farmakokinetična analiza ni pokazala, da bi starost kakorkoli pomembno vplivala na farmakokinetiko rosiglitazona ali glimepirida.
11 Hypersensitivity reactions of the skin may occur as itching, rash and urticaria. 
11 Pojavijo se lahko preobčutljivostne reakcije kože, npr. srbenje, izpuščaj ali urtikarija.
Pink, rounded triangular tablet with “gsk” debossed on one side and “4/4” on the other side. 
Rožnate, zaokrožene trikotne tablete z vtisnjeno oznako "gsk" na eni strani in "4/4" na drugi.
No animal studies have been conducted with the combined products in AVAGLIM. 
S kombinacijo zdravil v AVAGLIMU niso izvedli nobenih študij na živalih.
A study comparing AVAGLIM to monotherapy rosiglitazone or glimepiride demonstrated incremental benefit in control of glycaemia of the fixed-dose combination over monotherapy. 
Študija, v kateri so AVAGLIM primerjali z monoterapijo z rosiglitazonom ali glimepiridom, je pokazala, da kombinacija fiksnih odmerkov v primerjavi z monoterapijo prinaša dodatno korist pri uravnavanju glikemije.
Renal insufficiency: There are no clinically significant differences in the pharmacokinetics of rosiglitazone in patients with renal impairment or end stage renal disease on chronic dialysis. 
Insuficienca ledvic: Farmakokinetika rosiglitazona se pri bolnikih z okvaro ledvic ali končno boleznijo ledvic na kronični dializi ne razlikuje klinično pomembno.
• swelling (oedema) due to water retention. 
• oteklina (edem) zaradi zastajanja vode v telesu
Periodic haematological monitoring (especially leucocytes and thrombocytes) are required during 
Med zdravljenjem z AVAGLIMOM je potreben občasen hematološki nadzor (zlasti levkocitov in
No parent drug was recovered from urine or faeces. 
V urinu ali blatu se ni pojavilo nič matičnega zdravila.
MARKETING AUTHORISATION HOLDER SmithKline Beecham Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. 
Imetnik dovoljenja za promet z zdravilom: SmithKline Beecham Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija.
• rapid and excessive weight gain caused by fluid retention 
• hitro in močno povečanje telesne mase zaradi kopičenja tekočine v telesu
If you accidentally take too many tablets, contact your doctor or pharmacist for advice. 
Če ste vzeli večji odmerek zdravila Avaglim, kot bi smeli Če po nesreči vzamete preveč tablet, se posvetujte s svojim zdravnikom ali farmacevtom.
Studies with single oral doses in normal subjects and with multiple oral doses in patients with type 2 diabetes mellitus have shown significant absorption of glimepiride within 1 h after administration and Cmax at approximately 2.5 h. There is a linear relationship between dose and both Cmax and AUC. 
Študije s posamičnimi peroralnimi odmerki pri zdravih preiskovancih in z večkratnimi peroralnimi odmerki pri bolnikih z diabetesom mellitusom tipa 2 so pokazale pomembno absorpcijo glimepirida v 1 uri po uporabi in Cmax po približno 2,5 ure.
Transient visual disturbances may occur especially on initiation of treatment, due to changes in blood 
Zaradi sprememb vrednosti glukoze v krvi se lahko pojavijo prehodne motnje vida, še posebej na začetku zdravljenja.
No data are available with regard to overdose of AVAGLIM. 
Podatkov o prevelikem odmerjanju AVAGLIMA ni.
• reduction in the number of red blood cells, or a type of white blood cell (granulocytopaenia) 
• Zmanjšanje števila rdečih krvnih celic, ali ene vrste belih krvnih celic (granulocitopenija), ki je lahko huda (agranulocitoza) ali zmanjšanje števila vseh vrst krvnih celic (pancitopenija)
In addition, rosiglitazone preserved ß-cell function as shown by increased pancreatic islet mass and insulin content and prevented the development of overt hyperglycaemia in animal models of type 2 diabetes. 
Poleg tega je rosiglitazon v živalskih modelih diabetesa tipa 2 ohranil delovanje celic β, kot dokazujeta povečana masa pankreatičnih otočkov in vsebnost insulina, ter je preprečil pojav manifestne hiperglikemije.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with CYP2C9 as only a minor pathway. 
Študije in vitro kažejo, da se rosiglitazon presnavlja predvsem s CYP2C8, CYP2C9 pa je le manj pomembna pot.
Insulin should only be added to established rosiglitazone therapy in exceptional cases 
Zdravljenje z insulinom se lahko k že uvedenemu zdravljenju z rosiglitazonom uvede le v izjemnih primerih in pod
Driving and using machines Avaglim can make you dizzy or cause your blood sugar to become lower than normal (see ‘Low blood 
Vpliv na sposobnost upravljanja vozil in strojev Avaglim lahko povzroči omotico ali zniža normalno vrednost vašega krvnega sladkorja (glejte ‘Nizka vrednost krvnega sladkorja' v poglavju 4).
You must look out for certain symptoms while you are taking Avaglim, to reduce the risk of any problems. 
Da bi zmanjšali tveganje za pojav kakršnihkoli težav morate biti med jemanjem zdravila Avanglim pozorni na nekatere simptome.
Thiazolidinediones act primarily by reducing insulin resistance and sulphonylureas act primarily by stimulating release of insulin from functioning pancreatic β-cells. 
Primarni učinek tiazolidindionov je zmanjšanje odpornosti proti insulinu, primarni učinek sulfonilsečnin pa spodbujanje sproščanja insulina iz delujočih celic β v pankreasu.
Once glycaemic control is stable at these doses, AVAGLIM may be introduced at a starting dose of 4 mg rosiglitazone/4 mg glimepiride 
Ko je glikemija s temi odmerki urejena, je mogoče uvesti AVAGLIM v začetnem odmerku 4 mg rosiglitazona/4 mg glimepirida enkrat na dan.